Zentalis updates azenosertib program; DENALI Part 2 topline readout expected by year-end 2026

Zentalis Pharmaceuticals, Inc.

Completed enrollment in DENALI Part 2a, supporting registration-intended development of azenosertib.
Aligned with FDA on confirmatory ASPENOVA Phase 3 trial design for Cyclin E1-positive PROC.
Cash, equivalents and securities of $280.7M as of Sep 30, 2025; runway into late 2027.
2026 milestones: Part 2a dose confirmation H1, ASPENOVA initiation H1, Part 2 topline by YE.
DENALI Part 2, if successful, could support accelerated approval for azenosertib in PROC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.